Global Heparin Market Report 2023: Sector is Expected to Reach $12.8 Billion by 2031 at a CAGR of 4.4% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Heparin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

The global heparin market value in 2022 was USD 8.70 billion, driven by the ongoing research and development in heparin-based therapies the globe. The market size is anticipated to grow at a CAGR of 4.4% during the forecast period of 2023-2031 to achieve a value of USD 12.80 billion by 2031.

Heparin is a naturally occurring anticoagulant, widely used in medical practice to prevent and treat blood clots in various clinical settings. It is derived from animal tissues, primarily porcine intestinal mucosa or bovine lung.

Heparin plays a vital role in managing a range of conditions, including deep vein thrombosis (DVT), pulmonary embolism, and during surgical procedures such as coronary artery bypass grafting and dialysis. The heparin market is segmented into two main types: unfractionated heparin (UFH) and low molecular weight heparin (LMWH).

The global market for heparin has experienced substantial growth over recent years, driven by factors such as the increasing prevalence of chronic diseases, an aging population, and the growing demand for anticoagulant therapies. The market has also been influenced by ongoing research and development in heparin-based therapies, advancements in manufacturing processes, and supportive regulatory policies.

Market Segmentation

by Type

Low Molecular Weight Heparin

• Intravenous
• Subcutaneous

Ultra-Low Molecular Weight Heparin

• Intravenous
• Subcutaneous

Unfractionated Heparin

• Intravenous
• Subcutaneous

by Application

• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

by Mode of Administration

• Intravenous
• Subcutaneous

by End User

• Outpatient
• Inpatient

by Source

• Porcine
• Bovine
• Others

Key Trends in the Heparin Market

Some key trends of the market are as follows:

• Rising demand for low molecular weight heparin (LMWH): LMWH has gained popularity due to its higher bioavailability, more predictable anticoagulant response, and a lower risk of adverse effects compared to UFH. This has resulted in an increasing demand for LMWH in various therapeutic applications
• Technological advancements in heparin production: Ongoing research and development efforts have led to the discovery of novel heparin production methods and improved purification techniques, contributing to market growth
• Expansion of therapeutic applications: The development of heparin-based therapies for new indications, such as cancer treatment and wound healing, has further fuelled the market growth

Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the market are as follows:

• GlaxoSmithKline plc
• Pfizer Inc
• Leo Pharma A/S
• Sanofi S.A
• Dr. Reddy's Laboratories Ltd
• Aspen Pharmacare Holdings Limited
• B. Braun Melsungen AG
• Fresenius Kabi AG
• Sandoz (Novartis AG)
• Teva Pharmaceuticals
• Viatris Inc.

For more information about this report visit https://www.researchandmarkets.com/r/q9wkh3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.